Kaitlin Duffy - Verve Therapeutics Executive Resources
| VERV Stock | USD 5.78 0.47 8.85% |
Executive
Kaitlin Duffy is Executive Resources of Verve Therapeutics
| Address | 201 Brookline Avenue, Cambridge, MA, United States, 02215 |
| Phone | 617 603 0070 |
| Web | https://www.vervetx.com |
Verve Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2219) % which means that it has lost $0.2219 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4067) %, meaning that it created substantial loss on money invested by shareholders. Verve Therapeutics' management efficiency ratios could be used to measure how well Verve Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.28 in 2024. Return On Capital Employed is likely to drop to -0.33 in 2024. At this time, Verve Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 120.5 M in 2024, whereas Other Assets are likely to drop slightly above 3.9 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Daniel Anderson | Crispr Therapeutics AG | N/A | |
| Charlene JD | Editas Medicine | N/A | |
| Francis Lo | Adaptive Biotechnologies Corp | 43 | |
| Samarth Kulkarni | Crispr Therapeutics AG | 46 | |
| Julianne MBA | Crispr Therapeutics AG | N/A | |
| David MD | Intellia Therapeutics | 69 | |
| Amy MD | Beam Therapeutics | 60 | |
| Richard Mulligan | Sana Biotechnology | 69 | |
| Daniel Poon | Caribou Biosciences | N/A | |
| Bethany Cavanagh | Beam Therapeutics | N/A | |
| Paul MD | Sana Biotechnology | N/A | |
| Linea Aspesi | Editas Medicine | 54 | |
| Gopi Shanker | Beam Therapeutics | N/A | |
| Karina Calzadilla | Adaptive Biotechnologies Corp | N/A | |
| Allan MD | Prime Medicine, Common | 49 | |
| Cristi Barnett | Editas Medicine | N/A | |
| Ariel Hurley | Blueprint Medicines Corp | 50 | |
| MD FACP | Crispr Therapeutics AG | 50 | |
| Raju Prasad | Crispr Therapeutics AG | 40 | |
| Amy CFA | Caribou Biosciences | N/A | |
| Christina Rossi | Blueprint Medicines Corp | 47 | |
Management Performance
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.22 |
Verve Therapeutics Leadership Team
Elected by the shareholders, the Verve Therapeutics' board of directors comprises two types of representatives: Verve Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Verve. The board's role is to monitor Verve Therapeutics' management team and ensure that shareholders' interests are well served. Verve Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Verve Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jennifer Robinson, Vice Communications | ||
| Allison CPA, CFO Officer | ||
| Kaitlin Duffy, Executive Resources | ||
| Troy Lister, Chief Officer | ||
| MD MPH, CoFounder Advisor | ||
| Joan MBA, Chief Officer | ||
| FACC MD, CoFounder | ||
| Anthony MD, CoFounder Member | ||
| Allison Dorval, CFO Officer | ||
| Andrew JD, COO President | ||
| Andrew MD, Chief Officer | ||
| Sekar MD, CEO CoFounder | ||
| Margaret Beaudoin, VP Fin | ||
| Issi MBA, CoFounder Advisor | ||
| Burt MD, CoFounder Board |
Verve Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Verve Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (8.29) % | ||||
| Current Valuation | 20.69 M | ||||
| Shares Outstanding | 84.66 M | ||||
| Shares Owned By Insiders | 1.77 % | ||||
| Shares Owned By Institutions | 97.70 % | ||||
| Number Of Shares Shorted | 17.08 M | ||||
| Price To Earning | 5.45 X | ||||
| Price To Book | 0.96 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Verve Stock Analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.